Therapeutic drug development program for COVID-19

Phase 2

Active, not recruiting

• Conditions: COVID-19

• Registration Number: JPRN-jRCTs051200049
• Lead Sponsor: Iwahori Kota

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2020-08-26
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Not Recruiting
• Sex: All
• Target Recruitment: 42

Inclusion Criteria

1) Patients who are positive for SARS-CoV-2 by PCR or antigen test
2) Patients who do not need continuous (24h) oxygen inhalation
3) Patients who can eat and drink
4) Patients older or equal to 20 years old and younger than 75 years old
5) Patients who can sign the informed consent form by themselves

Exclusion Criteria

1) Patients with hypersensitivity for tetracycline compound
2) Patients showing SpO2 < 93% without oxygen inhalation
3) Patients who are or have a possibility to be pregnant, or hope to be pregnant during the study.
4) Patients with liver failure (AST and/or ALT >= the standard value)
5) Patients with kidney failure (eGFR < 30 ml/min/1.73m2)
6) Patients who had a COVID-19 vaccination
7) Patients who are considered unsuitable for the study by the PI or sub investigators

Study & Design

• Study Type: Interventional
• Study Design: Not specified